Melanotan I vs Exenatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Melanotan I
Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe sun sensitivity.
Full details →Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Side-by-Side Comparison
| Aspect | Melanotan I | Exenatide |
|---|---|---|
| Mechanism | Binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection without UV exposure. | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. |
| Typical Dosage | Clinical: 16mg implant every 2 months. Research protocols for tanning typically use 0.5-1mg daily for loading, then maintenance dosing. | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. |
| Administration | FDA-approved form is a subcutaneous implant. Research use involves subcutaneous injection. Often combined with minimal UV exposure to enhance results. | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. |
| Side Effects | Nausea (especially initially), facial flushing, fatigue, headache, and darkening of existing moles or freckles. | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). |
| Best For |